Abstract Neuregulin (NRG), an epidermal growth factor is known to promote the growth of various cell types, including human melanoma cells through ErbB family of tyrosine kinases receptors. Tanapoxvirus (TPV)-encoded protein TPV-15L, a functional mimic of NRG, also acts through ErbB receptors. Here, we show that the TPV-15L protein promotes melanoma proliferation. TPV recombinant generated by deleting the 15L gene (TPVD15L) showed replication ability similar to that of wild-type TPV (wtTPV) in owl monkey kidney cells, human lung fibroblast (WI-38) cells, and human melanoma (SK-MEL-3) cells. However, a TPV recombinant with both 15L and the thymidine kinase (TK) gene 66R ablated (TPVD15LD66R) replicated less efficiently compared to TPVD15L and the parental virus. TPVD15L exhibited more robust tumor regression in the melanoma-bearing nude mice compared to other TPV recombinants. Our results indicate that deletion of TPV-15L gene product which facilitates the growth of human melanoma cells can be an effective strategy to enhance the oncolytic potential of TPV for the treatment of melanoma.
Introduction
Melanoma is a common skin cancer with significant morbidity. It accounts for approximately 4 % of all skin cancers, but for nearly 80 % of all skin cancer-related deaths [1] [2] [3] . If not detected at the early stage, metastatic melanoma is highly aggressive with the five-year survival rate of approximately 15 % [4] . Significant progress has been made in the development of treatment options for melanoma, where current therapeutic options include surgery, chemotherapy, radiotherapy, immunotherapy, cryotherapy, and targeted drugs. Two such targeted drugs are FDA approved vemurafenib and dabrafenib (BRAF inhibitors) which inhibit a member of Raf kinase family, referred to as B-Raf. Most melanomas and nevi harbor the mutation in BRAF gene, which results in over-activation of B-Raf kinase involved in cell division. These advances have not significantly changed the survival of melanoma patients with advanced disease [5] . In the continuous quest for development of new therapeutic agents for melanoma, apoptosis-inducing agents and oncolytic viruses (OVs) are relatively new additions.
The OVs, which either selectively or preferentially infect and destroy tumor cells by lysis, and possibly by inducing an anti-tumor immune response, appear to be one of the most promising approaches to treat melanoma [6] [7] [8] . Some of the common broad strategies used during the development of OVs include increasing tumor selectivity and induction of a strong anti-cancer immune response. Infecting and replicating in tumor cells in a selective manner is an inherent feature of certain viruses. For viruses without significant native tumor specificity, oncoselectivity can usually be achieved by targeted genetic engineering to increase the viral tropism and/or the efficiency of replication in the cancerous cells [9, 10] . For example, thymidine Edited by Keizo Tomonaga.
kinase (TK) and ribonucleotide reductase (RR) are important for DNA synthesis and their levels of expression are elevated in cancerous cells as compared to normal cells [11] . Therefore, deletion of genes encoding TK and RR in OVs is a commonly used strategy to increase tumor selectivity of DNA viruses [9] . Further, OVs can be genetically modified and equipped to express immune stimulatory proteins, such as granulocyte-monocyte colony-stimulating factor (GM-CSF), macrophage chemotactic protein-1, flagellin, and interleukin 2 (IL-2), to activate the host innate and adaptive immune systems to trigger tumor regression [9, 11, 12] . Several DNA and RNA viruses, including vesicular stomatitis virus (VSV), adenovirus, and Newcastle disease virus (NDV), have been genetically modified and/or ''armed'' with immune-modulatory genes for use in advanced clinical trials [6, [13] [14] [15] [16] . A genetically engineered adenovirus (H101) was approved by China's State Food and Drug Administration (CFDA) in 2005 for treating head and neck cancer [17, 18] . Talimogene laherparepvec (T-VEC), a herpes simplex virus-1 (HSV) strain modified to express human GM-CSF, was approved by the U.S. FDA for melanoma treatment in October 2015 [19] .
Tanapoxvirus (TPV), which belongs to the family Poxviridae (genus Yatapoxvirus), is a large virus containing double-stranded (ds) DNA genome (approximately 144 kbp) [20] . TPV is antigenically distinct and does not immunologically cross react with other poxviruses, including vaccinia virus (VV). It causes a mild self-limiting disease in humans, and most of the global population (with the exception of equatorial Africa) is immunologically naïve. Additionally, no man-to-man transmission has been reported [21] [22] [23] . With a large genome for genetic modification and highly attenuated virulence, TPV can potentially serve as an ideal candidate for oncolytic virotherapy. Previous studies have revealed that poxviruses employ various strategies to modulate the host anti-viral immune responses, including the secretion of cytokine and cytokine-and/or chemokine-binding receptor homologs [24] [25] [26] [27] . It has been shown that a 45-kDa protein is encoded by the TPV-2L gene, which functions as a highaffinity inhibitor of human tumor necrosis factor (TNF) [28, 29] . Our previous studies have also shown that TPV-15L-encoded protein biologically mimics neuregulin (NRG). As one of the epidermal growth factors (EGF), NRG is the ligand for ErbB3 and ErbB4 which are associated with therapeutic resistance in many cancers, such as melanoma, breast cancer, and prostate cancer [30] [31] [32] [33] . We have also demonstrated that TPV-15L protein is capable of binding and phosphorylating the NRG receptor heterodimer ErbB2/3 in an established NRG bioassay [34] .
The ErbB family of tyrosine kinases receptors includes ErbB1 (epidermal growth factor receptor [EGFR]), ErbB2, ErbB3, and ErbB4 [35, 36] . The binding of ligands to the ErbB receptors leads to the formation of homo-or heterodimers and the activation of the intrinsic kinase domain. These activities, in turn, initiate a signal transduction cascade that ultimately leads to DNA synthesis and cell proliferation [37] [38] [39] . NRG specifically binds to ErbB3 and ErbB4 receptors. Binding of NRG to ErbB3/ ErbB4 changes the conformation of receptors and induces heterodimerization with ErbB2, which results in the activation of downstream signaling [40, 41] . ErbB3 expression has been found to be enhanced in malignant melanoma cells and is associated with poor prognosis and reduced patient survival rate [42] [43] [44] . NRG-treated melanocytes show increased proliferation and invasion, altered morphology, and increased expression of progression and metastasis genes [40] . Further, it has been shown that the knock-down of NRG results in significant inhibition of melanoma growth, and those melanoma tumors treated with anti-ErbB3 antibody showed slower proliferation [45] . Recent research advances have shown success with melanoma therapies targeting activated BRAF. It has been demonstrated that NRG is highly expressed in dermal fibroblast and cancer-associated fibroblasts, and enhances the growth of RAF-inhibited BRAF V600E/D melanoma cells. Further, the safeguarding effects of fibroblast-derived NRG on melanoma cells treated with RAF inhibitors can be impeded effectively by ErbB2-and ErbB3-neutralizing antibodies. Upregulation of ErbB3 and enhanced responsiveness to NRG were observed as a form of adaptive resistance to RAF/MEK inhibitors in mutant BRAF melanoma [46] [47] [48] [49] [50] . These studies provide a solid theoretical basis for targeting ErbB signaling in combination with RAF inhibitors in mutant BRAF melanoma [51] .
In this study, we show that the NRG mimicking protein encoded by the TPV-15L gene exhibits a similar growthpromoting effect in vitro on human mutant BRAF melanoma cells SK-MEL-3, which harbor BRAF V599E mutation and the elevated kinase activity of B-Raf. In light of this, we genetically engineered TPV with a 15L gene deletion and without/with the deletion of 66R gene that encodes TK, thus generating TPVD15L and TPVD 15LD66R, respectively. TPVD66R, with 66R/TK gene deletion was generated earlier in our laboratory [11] . Deletion of the 15L gene had no significant effect on TPV replication in vitro. However, TPVD15LD66R replicated less efficiently compared to wtTPV, TPVD66R, and TPVD15L. Our in vivo study showed that TPVD15L regressed human melanoma tumors in nude mice more significantly compared to that of wtTPV, TPVD66R, or TPVD15LD66R. Taken together, our results suggest that TPVD15L can be a promising candidate for oncolytic virotherapy of melanoma. 
Construction of the recombinant TPVs
A plasmid derived from a commercially available cloning vector pBluescript II KS (?) was used to include the genomic sequences flanking the right and left sides of TPV-15L open reading frame (ORF). The left flanking was generated by using polymerase chain reaction (PCR) with forward primer 5 0 -TAGGTACTCGAGAAAAACACCAA TA-3 0 (XhoI) and reverse primer 5 0 -GTTTAAATC GATGGACCTG-3 0 (ClaI). Two primers were designed for amplifying the right flanking as forward primer 5 0 -CAT ATTTTGCGGCCGCGGTAAACAATT-3 0 (NotI) and reverse primer 5 0 -GTTAAAAATGGAAAAGAGCTCT AATTTTAACAACAG-3 0 . A synthetic poxvirus early/late (E/L) promoter and a green fluorescence protein (GFP) gene were in between left and right flanking sequences. The plasmid was named as p15LGFP plasmid for generating a TPV-15L knockout virus (TPVD15L). This plasmid was transfected (Superfect transfection reagent; Qiagen) into 35-mm tissue culture dishes plated with OMK cell monolayer infected with wtTPV at 1 multiplicity of infection (MOI). The cells with transfection and infection were incubated at 37°C incubator with 5 % CO 2 until visible fluorescence caused by GFP expression appeared.
The virus was harvested, and recombinant virus TPVD15L was plaque purified at least three times until no visible nonfluorescence plaques and no 15L gene were detected by confirmation PCR. Plaque assays were carried out as described earlier [52] .
A second plasmid based on pBluescript II KS (?) was generated to produce a TPV-66R gene knockout virus. The left flanking and right flanking of 66R ORF were inserted in the plasmid, with an E/L synthetic promoter driving the expression of mCherry in between two flanking sequences. The left flanking was amplified using PCR with SacI forward 5
0 -AATGGATCACATAAAGGAGCTCTTAACG-3 0 and NotI reverse 5 0 -CAGAAAACATGCGGCCGCATA TAATCT-3 0 . The right flanking was generated using EcoRI forward 5
0 -GGAGATGAACAAGAAATAGAATTCATA GG-3 0 and HindIII reverse 5 0 -TGTTCTTTATCACAA GCTTCTATCGGGTG-3 0 . The generated plasmid was named as p66RmCherry plasmid. By using TPV genomic flanking sequences for either 15L or 66R, the engineered plasmid could be guided to a specific point where a targeted ablation occurs (ablation of 15L or 66R gene) with the simultaneous replacement of a fluorescent reporter (GFP/mCherry). All plasmids were confirmed by DNA sequencing.
This p66RmCherry plasmid was transfected into OMK cell monolayer infected with wtTPV at 1 MOI. By the process of transfection and infection, the recombinant virus TPVD66R was generated with visible fluorescence caused by mCherry expression. The virus was harvested, and TPVD66R was plaque purified at least three times by using a plaque purification assay, with the selection enabled by the expression of mCherry as described earlier [52] . Also, the p66RmCherry plasmid was transfected into TPVD15L-infected OMK cells, and recombinant TPV with both TPV-15L and TPV-66R ablated (TPVD15LD66R) was generated. TPVD15LD66R was plaque purified with the selection by both mCherry and GFP expression. The purity of the generated recombinant viruses was determined by confirmation PCR [11] . The TPV-15L deletion was confirmed by amplifying using internal forward primer Expression and purification of TPV-15L protein TPV-15L gene was amplified using forward primer 5 0 -GCGGGATCCATGAAAAACAAATTTATG-3 0 (BamHI) and reverse primer 5 0 -CGCTCGAGATTTACTATTTTAT TTTCAC-3 0 (XhoI). The 15L amplicon was cloned into pcDNA3.1/myc/His ver C (Invitrogen), producing a fusiontagged construct which was subsequently cloned into the pFastBac-Dual-eGFP cassette. Recombinant baculovirus was generated using Bac-to-Bac system (Invitrogen). The recombinant baculovirus was used to infect sf21 insect cells and the cell supernatant was collected, and TPV-15L protein was purified using a hexa-His Co 2? chelate resin affinity column (BD Sciences) routinely employed in our laboratory [34] .
Growth of human melanoma cells in the presence of TPV-15L protein
Human melanoma cells (SK-MEL-3) were plated in a 96 well plate in McCoy's 5A medium with 15 % FBS and incubated overnight at 37°C with 5 % CO 2 in humidified chambers. The next day, cells were switched to the serumfree McCoy's 5A medium and incubated for 24 h before the addition of NRG or TPV-15L protein. Cells were treated with either TPV-15L purified protein (500 ng/ml) or NRG (500 ng/ml). Untreated cells were used as mock. Total number of viable cells was determined in each group at day 1, 3, and 5 post-treatment, by counting cells on a hemocytometer chamber using trypan blue stain to exclude non-viable cells. Each experiment was repeated three times independently and standard deviations were calculated.
Replication of TPV recombinants
Virus replication was determined in OMK, WI-38, and SK-MEL-3 cells. Cell monolayers planted in 24-well plates were infected with wtTPV or one of the recombinants of TPV (TPVD66R, TPVD15L, and TPVD15LD66R) at 0.1 and 5 MOI. Infected cells were harvested at 49, 96, and 240 h post infection (hpi), and total virus titer was determined by viral plaque assay on OMK monolayers in 6-well plates. Each experiment was repeated three times.
Animals
Male athymic nude mice (Crl:NU(NCr)-Foxn1 nu ) were purchased from Charles River company (Wilmington, Massachusetts, USA) at 6-8 weeks of age. Mice were housed individually with food and water available in pathogen-free animal facility at Western Michigan University. Animals were allowed to acclimatize for 1 week before experimentation. All protocols for treatment and manipulations were approved by the Institutional Animal Care and Use Committee of Western Michigan University (IACUC protocol number 13-07-01).
Virotherapy of human melanoma tumor xenografts
Melanoma tumors were induced in nude mice by injecting 5 9 10 6 viable SK-MEL-3 cells suspended in 100 ll of phosphate saline buffer (PBS), subcutaneously on the dorsal surface in the inter-scapular region. Cell viability assays were conducted using trypan blue following each injection to test the cell viability. Tumor volume was calculated by using the digital calipers to measure three-dimensionally according to the formula [4/ 3 9 3.1415 9 (length/2) 9 (width/2) 9 (height/2)] in mm 3 . Mice were randomly segregated into control and experimental groups, when the tumor size reached 45 ± 4.5 mm 3 , with each group containing five mice (n = 5). The number of animals per group was determined by power analysis, and n of 5 is standard procedure for in vivo experiments including quantitative pathology. Each mouse in experimental group received a single intratumoral injection of 5 9 10 6 pfu virus particles in 100 ll medium. Animals in mock group received 100 ll medium only. The day of treatment administration was considered as day 0, and mouse weights and tumor volumes were measured and recorded every day. All the mice were sacrificed at 35 days post-treatment, and the tumors were harvested. The blood sample of each mouse was collected and centrifuged for the collection of the serum. Tumors were weighed and stored for histological analyses.
Statistical analysis
All in vitro experiments were done in triplicates and the measurements were presented as mean ± SD. The twosample unequal variance Student's t test analysis was applied for testing the differences. The significance level used was P \ 0.05. Student's t-test was used for assessing the treatment effect of each experimental virotherapy group compared to the mock group in vivo. The tumor volumes of each experimental group were compared with those in the mock group, and significance was considered if P \ 0.05.
Results

TPV-15L protein and NRG increase melanoma cell proliferation
We have shown that TPV-15L is a secreted early protein that phosphorylates NRG receptors and binds to heparin Virus Genes (2017) 53:52-62 55 [34] . Since NRG has also been shown to promote melanoma progression and metastasis [40] , we sought to investigate if TPV-15L protein could have a similar effect on melanoma cells. SK-MEL-3 cells in the serum-free medium were treated with NRG or TPV-15L protein (500 ng/ml) and incubated for 1, 3, and 5 days. Cells in the control wells received no treatment. Compared to control, cell numbers of those treated with NRG and TPV-15L were significantly higher as early as on day 1 (P \ 0.05). At day 3, SK-MEL-3 cells treated with NRG and TPV-15L increased by 110 and 86 %, respectively, demonstrating continued proliferation, while those with no treatment achieved only 2.5 % growth. At day 5, NRG-and TPV-15L-treated cells achieved 125 and 120 % growth, respectively, while those with no treatment gained only 69 % growth (Fig. 1) . These results provide compelling evidence that TPV-15L protein, like NRG, promoted melanoma growth. The proliferative efficacy of TPV-15L was indistinguishable from NRG (P \ 0.05).
Generation of TPVD15L and TPVD15LD66R
In the light of functional similarities between TPV-15L protein and NRG in enhancing melanoma proliferation, we sought to delete 15L gene from TPV (TPVD15L) and to test as an OV for melanoma virotherapy. The recombinant virus TPVD15L was plaque purified at least three times until no visible wtTPV plaques appeared. Deletion of 15L ORF was then confirmed by PCR. Similarly, ORF 66R which encodes TK was deleted from TPVD15L. TK is present in abundant quantities in cancerous cells and its deletion from virus has widely been used to enhance tumor selectivity of DNA viruses [9] . For this purpose, TPVD15L-infected cells were transfected with p66R-mCherry plasmid-containing mCherry reporter gene under E/L synthetic promoter. The resulting TPVD15LD66R was plaque purified at least three times as previously described. The exhibition of both mCherry and GFP was confirmed by fluorescence microscopy. The deletions of both 15L and 66R genes were further confirmed by PCR, using primers described in Materials and Methods. Figure 2 shows that wtTPV contained both 15L and 66R ORFs, while ORF 15L was deleted from TPVD15L. Similarly, ORF 15L and ORF 66R were absent in TPVD15LD66R. ORF 136R was used as a positive control in these experiments and was present in all three viruses, namely wtTPV, TPVD15L, and TPVD15LD66R. Ampicillin gene contained in plasmid was amplified in all three viruses to exclude single-crossover recombinants. These experiments provide compelling evidence that 15L and/or 66R gene were deleted, and that these viruses were generated as a result of double-crossover recombination events during transfection and infection. PCRs were used for verifying the ablations of 15L and 66R genes. Genomic DNA from each virus was isolated and probed for sequences internal in 15L, 66R, 136R, and ampicillin genes. Genes ablated showed no bands in the gel. TPV-15L internal fragment is 197 bp; 66R region is 379 bp; and 136R internal fragment used as a control has a predicted amplicon length of 531 bp. Ampicillin gene was probed for determining the insertion of ampicillin or other genes from plasmid into viral DNA during the transfection-infection process when homologous recombination occurs. Lanes: wtTPV (control); TPVD15L (15L is ablated); TPVD15LD66R (both 15L and 66R are ablated). Moreover, no insertion of ampicillin gene is shown in the viral DNA of TPVD15L and TPVD15LD66R
Replication of TPV recombinants in human and monkey cells
Replication curves of wtTPV, TPVD66R, TPVD15L, and TPVD15LD66R were generated using 0.1 and 5 MOI in OMK cells and human fetal lung fibroblasts (WI-38) and are shown in Fig. 3 . The infected cells were harvested, and virus was titrated on OMK monolayers at 48, 96, and 240 hpi. The first time point for harvesting (48 hpi) was decided based on the eclipse phase period of TPV which is around 48 hpi, as TPV unlike VV is a slow replicating virus [52] . Results in Fig. 3 showed similar titers which were lower compared to those of wtTPV. The above data supports the earlier results that (1) TPV-15L is non-essential for the replication of TPV in cell culture, and that (2) deletion of TPV-66R adversely affects the viral replication.
Replication of TPVD15L and TPVD15LD66R in SK-MEL-3 cells
The replication characteristics of TPVD15L and TPVD15LD66R were also examined in BRAF mutant melanoma SK-MEL-3, and compared with wtTPV and TPVD66R. SK-MEL-3 cells were infected at 0.1 and 5 MOI and the total virus titer was determined at 48, 96, and 240 hpi. As shown in Fig. 4 , at 0.1 MOI, the replication of TPVD15L displayed a slight delay in the onset of the replication. However, the virus titer of TPVD15L reached a similar level as wtTPV at 96 hpi. In contrast, TPVD66R and TPVD15LD66R replicated less efficiently compared to wtTPV and TPVD15L. At 96 hpi, the titer of TPVD15LD66R was fivefold to sixfold lower compared to TPVD15L and the titer of TPVD66R was threefold to fourfold lower compared to that of TPVD15L. At 5 MOI, TPVD15L exhibited similar replication kinetics with wtTPV. At 96 hpi, virus titers reached the maximum, with the titer of TPVD15L being twofold to threefold higher compared to that of TPVD66R and threefold to fourfold higher compared to that of TPVD15LD66R. The results showed that deletion of 66R gene but not 15L gene resulted in a significant delay of TPV replication in SK-MEL-3 melanoma cells in vitro.
Oncolytic virotherapy of human melanoma tumors xenografted in nude mice
To evaluate the oncolytic effectiveness of wtTPV and TPV recombinants, human melanoma tumors were induced by injecting BRAF mutant SK-MEL-3 cells subcutaneously on the dorsal surface in the inter-scapular region of athymic nude mice. Treatments consisted of intratumoral mock or virus injections, when the tumor volumes reached 45 ± 4.5 mm 3 . While mock-treated tumor xenografts continued to grow exponentially, xenografts treated with viruses exhibited continued but slow tumor growth. As shown in Fig. 5 , there were significant differences in the tumor growth between virus-treated groups and mock group (P \ 0.05). Compared to mock-treated tumors achieving nearly 552 % growth, tumors treated with wtTPV and TPVD66R displayed 250 and 244 % growth, respectively, after 35 days of treatment. TPVD15L produced significantly greater tumor growth delay compared to wtTPV and TPVD66R (P \ 0.05). At 35 days posttreatment, TPVD15L-treated tumors exhibited only 68 % growth compared to day 0. Interestingly, TPVD15LD66R
showed markedly less tumor growth inhibition efficacy (286 % tumor growth) compared to TPVD15L, perhaps due to the poor replication of the virus when ORF 66R was deleted (Figs. 3, 4) . These results showed that TPVD15L was able to significantly reduce the tumor progression at more time points in comparison to the mock than other TPVs. We believe that the enhanced oncolytic potential of TPVD15L was due to deletion of TPV-15L gene which encodes a viral protein that contributes to melanoma proliferation, as demonstrated by our in vitro studies. As TPV replicates only in humans and monkeys, nude mice with xenografted melanoma tumors were not suitable for studies related to the bio-distribution and safety of the virus.
Discussion
In the search for novel anti-cancer strategies, OVs have emerged as one of the most promising therapeutic options to eliminate cancer cells. They also overcome tumor-induced immune evasion in host and elicit an effective antitumor immune response. Viruses which are under evaluation for therapeutic purposes can be divided into two major groups: (a) viruses that possess a degree of innate oncoselectivity, such as reovirus, VSV, and NDV [10, [54] [55] [56] , and (b) viruses which require genetic modifications to enhance their tumor selectivity and immune stimulatory capability, such as VV with ablation of TK gene [57, 58] . Although OVs have shown encouraging results in experimental and clinical trials, the efficacy of an OV is still potentially limited by several factors. First, the anti-viral immune response developed by the host immune system, such as the induction of neutralizing anti-viral cellular and humoral immune responses, inactivates the virus and impedes the effectiveness of virus administered systemically. The ''barriers,'' such as neutralization and sequestration of the virus, make it uncertain for OVs to be ''one shot'' therapeutic agents, and also make that virus less effective during successive treatment cycles. Strategies have been devised to prime the immune response with one viral vector and boost with another vector, in order to focus the immune response on the tumor antigens and avoid antiviral immune responses [59, 60] . Although an effective virus-specific immune tolerance strategy will ultimately solve this issue, presently it may be necessary to have a set of antigenically distinct OVs for serial injections to avoid this problem. Second, the safety profile of a virus determines its feasibility as the virotherapy, and transmission from human to human in combination of continued virus evolution pose a serious concern for virus application. Only a small number of viruses, such as HSV and adenovirus, have been demonstrated as safe for application in clinical trials [54] . In light of these concerns, TPV appears to be an ideal OV candidate due to its characteristics. These include: (1) most of the global population is immunologically naïve to TPV, (2) TPV causes a mild, self-limiting febrile disease in humans making it relatively safer to use, (3) TPV is not transmitted from human to human, and (4) the large genome size of TPV (144 kbp) allows incorporation of several immune stimulatory transgenes. At present, advanced malignant melanoma is one of the diseases with very few effective treatments. Although significant advances have been made in monitoring and treatment of melanoma, the mortality associated with the disease remains largely un-altered [5] . Due to the limited efficiency and significant side effects of chemotherapies, a variety of immunological approaches have been devised, among which interferon-a (IFN-a) and IL-2 have shown significant efficacy and have been approved by U.S. FDA for melanoma treatment [61] [62] [63] . The OVs appear to be an appealing addition to melanoma therapies, due to the viral oncoselectivity and lysis of tumor cells [13] . Combination . Mice in the experimental groups were treated with intratumoral injections of 5 9 10 6 pfu of virus, while the mice in the mock group were intratumorally injected with medium only. Tumor volumes were measured using the digital calipers every day. In each graph shown here, the y-axis represents the average percentage of tumor growth (%) and the x-axis is time (days post virotherapeutic treatment). All experimental groups are compared to the mock group in which the mice were treated with only medium injection. Bars show the standard error of the mean (± 1 SEM). Points indicated with an asterisk (*) refer to tumor growth that was significantly reduced from the control (P B 0.05). Asterisks were marked every 3 days if there was significance. a wtTPV b TPVD66R c TPVD15L d TPVD15LD66R
Virus Genes (2017) 53:52- 62 59 of virotherapy and other therapies, such as chemotherapy, have also shown synergistic effects [64] . Our previous studies of TPV genomic analyses revealed that TPV-66R gene encodes TK, and that TPV-15L gene encodes EGF-like growth factor often referred to as NRG [34, 65] . Further, we have demonstrated that TPV-15L protein functions as a mimetic of NRG, capable of binding and phosphorylating the most potent NRG heterodimer receptor ErbB2/3 [34] . Elevated NRG levels have been shown to contribute to melanoma proliferation by binding to ErbB3, while melanoma treated with anti-ErbB3 has shown reduced cell proliferation [30, 45] . Thus, it would be interesting and worthwhile to further explore the application of neutralizing agents against ErbB receptors or NRG for melanoma therapy.
A variety of virokines carrying EGF-like sequence, such as vaccinia virus growth factor and myxoma virus growth factor, have been demonstrated to act on ErbB receptors and promote cell proliferation [66, 67] . In this study, we showed that TPV-15L protein and NRG both significantly increased the proliferation of the human melanoma cells (SK-MEL-3) in vitro. This further supports our earlier claim about the functional similarity between TPV-15L and NRG. In the light of these findings, we deleted TPV-15L gene both with and without the deletion of TPV-66R (TK) gene, generating two TPV recombinants TPVD15L and TPVD15LD66R. The replication kinetics of TPVD15L and TPVD15LD66R was studied in OMK, WI-38, and SK-MEL-3 cells. We demonstrated that TPVD15L had similar replication efficacy as wtTPV and that TPVD15LD66R replicated less efficiently compared to TPVD15L and wtTPV. The data supports our earlier results showing that TPV-15L is a nonessential gene for TPV replication and that TPV-66R exerts more significant effect on viral replication [34] .
We further studied whether deletion of TPV-15L gene (encoding NRG mimicking protein) will abolish the growth-promoting effect of TPV-15L protein on human melanoma cells (SK-MEL-3), and enhance oncolytic efficacy of TPV in melanoma-bearing nude mice. Tumor xenografts were established using SK-MEL-3 cells, which were treated with intratumoral injection of wtTPV, or one of the TPV recombinants (TPVD66R or TPVD15L or TPVD15LD66R). Our results demonstrated that TPVD15L exhibited a more robust tumor reduction compared to wtTPV, TPVD66R, and TPVD15LD66R. TPVD15LD66R was less effective in regressing tumor, possibly due to its slower replication, which has been demonstrated in vitro. The greater tumor reduction efficacy of TPVD15L compared with wtTPV and other TPV recombinants suggests that (1) the reduced melanoma proliferation possibly relates to the absence of tumor-enhancing properties caused by TPV-15L protein, and that (2) deletion of viral genes encoding NRG-like proteins is potentially an effective strategy to be used in genetic engineering of OVs for melanoma. Considering the pathological power of abnormal ErbB signaling and its contribution to oncogenesis in cancer biology, deletion of EGF-like growth factor genes from certain OVs and/or blocking the ErbB receptors would likely offer additional tumor suppression effects for oncolytic virotherapies. Similarly, Saydam et al. [68] have shown that HSV expressing small interference RNA (siRNA) directed against EGFR inhibits human glioblastoma cell growth more significantly compared to the control virus both in vitro and in vivo.
The results of this study warrant further investigation of TPVD15L as an effective vector for oncolytic virotherapy, while more strategies could be incorporated to further enhance its oncolytic efficacy in the therapy of melanoma and other cancers. TPV-2L gene encodes a 38 kDa secretory protein which binds and neutralizes TNFa [29] with high affinity [28] . It has been shown that TNF downregulates the expression of ErbB2 in pancreatic tumor cells, which demonstrates the inverse relation between TNF and ErbB2 [69] . In addition, ErbB2 overexpression induces resistance of breast cancer cells to the cytotoxic effect of TNFa [70] . Therefore, it would be appropriate to consider the construction of an oncolytic TPV recombinant with both 15L and 2L genes ablated, which will synergistically decrease the ErbB-related tumor proliferation and increase the viral oncolysis. Also, it is conceivable to delete TPV-136R gene encoding type I IFN binding receptor from TPVD15L backbone, as host IFN will potentially be ''saved'' from being neutralized and exert antiproliferative efficacy.
Coupling viral oncolytic activity with immune cells recruitment proves to be another attractive strategy for attaining the optimal clinical efficacy. Oncolytic VV JX-594 and more recently Amgen's oncolytic HSV, T-vec, are both armed with GM-CSF, suggesting the clinical benefit of enhancing host anti-tumor immunity [8] . In addition to virotherapies expressing GM-CSF, many other viruses expressing cytokines, such as IL-2, IL-12, and IL-24, have shown encouraging tumor regression efficacy [9, 71, 72] . Other strategies, such as promoting virus spread and increasing cytotoxicity, have also been applied in OV modification. Engineered virus expressing relaxin and decorin, known as extracellular matrix-modulating proteins, have shown enhanced penetration, persistence, and spread compared to the control virus in melanoma, glioma, and lung cancer [73, 74] . Introduction of suicide genes, such as FCU1-encoding bifunctional fusion protein which converts non-toxic 5-FC to toxic 5-fluorouracil and 5-fluorouridine monophosphate, has also been proven to be a feasible strategy for enhancing OV's effectiveness in different cancers [75] . Based on these findings and the oncolytic efficacy of TPVD15L shown in this study, we speculate that the modifications described above to TPV or TPVD15L may further improve the outcome of TPV as an oncolytic virotherapy.
